Treatment selection for MBC is based on biomarkers including hormone-receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, and individual patient and clinical characteristics that may include tumor burden, timing of disease recurrence, and the type of prior adjuvant therapies. Here, ERBB2 is linked to neoplasm.